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Background: Ventricular tachyarrhythmias are the most common and often the first
manifestation of coronary heart disease and lead to sudden cardiac death (SCD).
Early detection/identification of acute myocardial ischaemic injury at risk for malignant
ventricular arrhythmias in patients remains an unmet medical need. In the present study,
we examined the sphingolipids level after transient cardiac ischaemia following temporary
coronary artery occlusion during percutaneous coronary intervention (PCI) in patients and
determined the role of sphingolipids level as a novel marker for early detection of human
myocardial ischaemic injury.
Methods and Results: Venous samples were collected from either the coronary sinus
(n = 7) or femoral vein (n = 24) from 31 patients aged 40–73 years-old at 1, 5min, and
12h, following elective PCI. Plasma sphingolipids levels were assessed by HPLC. At
1min coronary sinus levels of sphingosine 1-phosphate (S1P), sphingosine (SPH), and
sphinganine (SA) were increased by 314, 115, and 614%, respectively (n = 7), while
peripheral blood levels increased by 79, 68, and 272% (n = 24). By 5min, coronary sinus
S1P and SPH levels increased further (720%, 117%), as did peripheral levels of S1P alone
(792%). Where troponin T was detectable at 12 h (10 of 31), a strong correlation was found
with peak S1P (R2 = 0.818; P < 0.0001).
Conclusion: For the first time, we demonstrate the behavior of plasma sphingolipids
following transient cardiac ischaemia in humans. The observation supports the important
role of sphingolipids level as a potential novel marker of transient or prolonged myocardial
ischaemia.
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INTRODUCTION
Despite recent advances in preventing sudden cardiac death
(SCD) due to cardiac arrhythmia, its incidence in the popula-
tion at large has remained unacceptably high. It is responsible for
50% of themortality from cardiovascular disease in the developed
countries and accounts for 300,000 to 400,000 deaths every year
in the United States. About 80% of SCDs are caused by ventric-
ular tachyarrhythmias that often occur without warning, leading
to death within minutes in patients who do not receive prompt
medical attention. It is the most common and often the first man-
ifestation of coronary heart disease. Early detection/identification
of acute myocardial ischaemia in patients at risk for lethal ven-
tricular arrhythmias remains an unmet medical need. At in vivo,
acute myocardial ischaemia is associated with dramatic electro-
physiological alterations that may lead to malignant ventricular
arrhythmias which occur within minutes of cessation of coronary
flow and are rapidly reversible with reperfusion. This suggests that
subtle and reversible biochemical and/or ionic alterations within
or near the sarcolemma of myocardium during the early stage of
acute ischaemic injury may contribute to the electrophysiological
instability.
Sphingolipids are biologically active lipids (Alewijnse and
Peters, 2008), whose serum sphingosine (SPH) levels were found
to be elevated in animal models of myocardial infarction (MI;
Zhang et al., 2001; Thielmann et al., 2002) and are thought
to have an important cardioprotective role during the ischemic
insult (Karliner et al., 2001). Sphingosine 1-phosphate (S1P) has
been shown to be an important mediator of ischemic pre- and
post-conditioning in both pharmacological and knockout ani-
mal studies (Karliner, 2009), with SIP receptors being expressed
in the myocardium, endothelium, and platelets (Karliner, 2009).
Deutschman et al. (2003) reported that sphingolipid levels are ele-
vated in patients with coronary artery disease (CAD) and that S1P
had a greater predictive value in detecting CAD, than traditional
risk factors. It is not clear whether sphingolipids are markers of
the inflammatory process associated with atherosclerotic CAD
and/or are markers of cardiac ischaemia associated with flow
obstructive coronary artery lesions. During coronary occlusion
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and subsequent reperfusion such as occurs during treatment of
MI with percutaneous coronary intervention (PCI), reactive oxy-
gen species (ROS) are formed that mediate ischaemia-reperfusion
injury based on oxidative stress (Nikolic-Heitzler et al., 2006).
ROS regulate S1P levels through changes in the function of
sphingosine kinase, the final rate limiting step in S1P synthe-
sis (Maceyka et al., 2007). Using samples collected from humans
before and after balloon occlusion of coronary arteries during PCI
we have for the first time investigated whether sphingolipids are
elevated during brief periods of coronary occlusion and there-
fore transient cardiac ischaemia, hence providing novel insight
into pathophysiological mechanisms that occur during ischaemia
reperfusion injury and determined whether change of their level
can be a novel marker for early detection of human myocardial
ischemic injury. To understand whether oxidative stress during
this transient ischaemia may potentially account for changes in
sphingolipids level we also evaluated changes in oxidized LDL
(Ox-LDL) used here as an oxidative stress biomarker.
METHODS
STUDY PROTOCOL
This study complies with the Declaration of Helsinki, was
approved by the North West 8 Research Ethics Committee
of Greater Manchester East and all patients gave written
informed consent before entry. Ethical approval was obtained
from the National Research Ethics committee via the NRES
committee-North West Greater Manchester Central, REC ref-
erence 07/H1008/162. Blood samples were obtained from 31
patients aged 40 to 73 years-old undergoing elective PCI to native
coronary arteries at the Manchester Heart Centre, Manchester,
UK. Procedures were performed via the femoral artery through
standard 6Fr sheaths and peripheral venous samples were col-
lected through a 6Fr femoral venous sheath. Coronary sinus sam-
pling was performed using a 6Fr Amplatz Left-1 catheter (AL-1)
during PCI. Control venous blood samples were obtained either
from the coronary sinus (7 patients) or via the femoral venous
sheath (24 patients) once the guide catheter and guide wire were
in position prior to the PCI procedure. Balloon inflations of
between 30 s and 1min were performed to predilate the target
lesions. Serial venous samples were then collected from either
the coronary sinus or femoral vein at 1 and 5min post-balloon
inflation. PCI was then completed as per routine at our center.
Twelve hour post-procedure samples to measure sphingolipid and
troponin T levels were taken from a peripheral vein.
After PCI, blood samples were immediately dispensed into
3ml ethylenediaminetetraacetic acid (EDTA) tubes with 2-
chloroadenosine (0.05mmol/liter) and procaine hydrochloride
(0.154mol/liter) and equilibrated at 4◦C. All blood samples col-
lected were centrifuged briefly to clarify and kept at 4◦C. Once
samples are derivatized, they were diluted into the mobile phase,
kept at 0–4◦C, and analyzed by HPLC as soon as possible. As
an added precaution, standards were alternated with samples to
detect (and correct for) losses over time.
Only patients with angiographic single vessel disease undergo-
ing elective PCI participated in this study, and had documented
normal left ventricular and renal function. Patients with history
of coronary artery bypass graft (CABG), valvular heart disease, or
MI/acute coronary syndrome (ACS) were excluded as were PCI
procedures in patients with chronic total occlusions. Peripheral
blood samples were also taken from 11 healthy controls with no
history of CAD.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
S1P standards were purchased from Avanti Polar Lipids, Inc.
(Delfzyl, The Netherlands). All other chemicals, including
o-phthaldialdehyde (OPA), D-sphingosine, D-erythro-
dihydrosphingosine, boric Acid, β-mercaptoethanol were
purchased from Sigma-Aldrich (Dorset, UK). All solvents for
high-performance liquid chromatography (HPLC) were pur-
chased from Fisher Scientific (Leicestershire, UK). All blood
samples collected into EDTA with 2-chloroadenosine and pro-
caine during the procedure were centrifuged at 2056 g for 15min
at 4◦C. Aliquots of plasma (0.5ml) were stored at −80◦C until
analyzed by HPLC. Sphingolipids were extracted from samples
and HPLC analysis of sphingolipids (S1P, SPH, and SA) levels
were performed according to Caligan et al. (2000).
DETERMINATIONOF TROPONIN T AND HIGH SENSITIVE TROPONIN
T (hsTnT)
Troponin T level in peripheral vein at 12 h after post-PCI was
measured by standard assay (Roche Troponin T). The level of
high sensitive troponin T (hsTnT) in samples from both the
coronary sinus and femoral vein at 1 and 5min after post-PCI
was also measured by High-Sensitive Troponin T assay (Roche
Diagnostics; Helleskov Madsen et al., 2008). The lower detec-
tion limits of standard and hsTnT assays are 0.01 ug/l and 5 ng/l,
respectively.
DETERMINATIONOF Ox-LDL AND hsCRP
Ox-LDL was measured by a commercially available sandwich
ELISA (Mercodia) with specific monoclonal antibody mAb-4E6
as described by Holvoet et al. (1998). A standard curve show-
ing the binding range of Ox-LDL samples was prepared. Internal
controls consisting of high and low standard plasma samples
were included on each microtiter plate to detect potential vari-
ations between microtitration plates. Each sample was assayed in
triplicate. The intra-assay coefficients of variation for all assays
were 5–9%. High resolution CRP (hsCRP) was measured using
a high-sensitivity assay with reagents and a BNII analyzer from
Dade-Behring, Milton Keynes, UK. The intra- and inter-assay
coefficient of variation for the hsCRP assay was 3.9 and 4.6%,
respectively.
STATISTICAL ANALYSIS
All data are reported as means± sem. Repeated measure One-
Way ANOVA was used to compare values of measurements
between groups. When analysis of variance revealed a significant
difference among values, Tukey’s test was applied to determine
the significance of a difference between selected group means.
P < 0.05 was taken to indicate statistical significance.
RESULTS
Blood samples were taken from total of 31 study participants
undergoing routine elective PCI. Characteristics and coronary
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lesion data of the study cohort are presented in Table 1.
Pre-dilation of the target lesions was performed with angio-
plasty balloons inflated between 14 and 22 Atmospheres (mean
15 Atmospheres) for a period of between 28 and 40 s (mean
31.1 s). During balloon inflation ischemic ECG changes were
noted in 20/31 patients (64.5%) with ST elevation in 13/31
patients (41.9%, mean ST elevation 0.5mm) and ST depression
in 7/31 patients (22.5%, mean ST depression 0.5mm). In the
remaining 11/31 patients (35.4%) no ECG changes were observed
although all patients reported transient chest discomfort during
this period.
Using HPLC we analysed plasma levels of sphingolipids in
patients at baseline (pre-balloon inflation) and at different time
course points after balloon inflation (1, 5min, and 12 h). HPLC
Table 1 | Characteristics and coronary lesion data of the study cohort
(n = 31).
DEMOGRAPHICS
Age (Years; mean ± SEM) 63 ± 9
Sex (% Male) 97
Caucasian (%) 87
% Normal LV function (EF > 60%) 100
% Normal renal function 100
RISK FACTORS
Hypertension (%) 53
Diabetes (%) 15
Hyperlipidemia (%) 85
Smoking (%) 39
BMI (kg/m2) 27.4 ± 4.8
MEDICATION
Antiplatelet therapy (%) 100
B-Blockers (%) 82
ACEi (%) 65
Statins (%) 100
Nitrates (%) 22.5
Ca Blockers (%) 29.5
TARGET VESSEL
LAD 21/37 (67.7%)
RCA 8/31 (25.8%)
Cx 2/31 (6.4%)
VESSEL DIAMETER
2.5–2.99mm 12/31 (38.7%)
3–3.49mm 11/31 (35.4%)
3.5–3.99mm 7/31 (22.5%)
4.5–4.99mm 1/31 (3.2%)
LESION LENGTH
10–14mm 4/31 (12.9%)
15–19mm 5/31 (16.1%)
20–24mm 11/31 (35.4%)
25–30mm 8/31 (25.8%)
>30mm 8/31 (25.8%)
% STENOSIS
50–74% 2/31 (6.4%)
75–94% 22/31 (70.9%)
>95% 7/31 (22.5%)
analysis revealed significant alterations in plasma levels of sph-
ingolipids sampled from the coronary sinus from 7 patients and
peripheral veins from 24 patients following induction of tran-
sient myocardial ischaemia by balloon occlusion of target lesion.
Representative examples of isolation and detection of sphin-
golipids, at baseline and at different time course points after
balloon inflation are shown in Figures 1A,B. Baseline concentra-
tions of S1P measured from peripheral blood samples were more
than 4-fold higher in patients with documented CAD under-
going PCI compared to healthy controls (1.29 ± 0.27 vs. 0.38
± 0.05μmol/liter; n = 11; P < 0.001; Figure 1C). As illustrated
in Table 2, there was a significant increase in all three sphin-
golipid levels at 1 and 5min, compared with baseline levels, both
in coronary sinus blood (Figures 2A,B,C) and peripheral blood
(Figures 2D,E,F). S1P showed the largest increase of the three
sphingolipids, with its greatest level at 5min (Figures 2A,D),
whereas the levels of SPH and SA were highest at 1min and began
to decrease at 5min (Figures 2B,C,E,F).
At 1min following balloon inflation, in coronary sinus, levels
of S1P, SPH, and SA increased by 314, 115 and 614%, respectively,
compared with baseline levels (n = 7, all P < 0.001), whereas
in peripheral blood, levels of S1P, SPH, and SA increased by
79, 68, and 272%, respectively, compared with baseline levels
(n = 24, all P < 0.001). Peripheral sphingolipid levels at 1min
were consistently very much lower than coronary sinus levels. At
5min after balloon inflation, in coronary sinus blood, levels of
S1P, SPH, and SA increased by 720, 117, and 320% compared
with baseline levels (n = 7, all P < 0.001), while in peripheral
blood, levels of S1P, SPH, and SA increased by 792, 44, and
56% compared with baseline levels (n = 24, all P < 0.001). At
12 h following the PCI procedure, peripheral levels of S1P were
much lower than that at 1 or 5min, but were still elevated
compared to baseline [S1P: by 88% (n = 24, all P < 0.001)].
Peripheral SPH and SA levels had declined to below baseline
(decrease of SPH: 33% n = 24, all P < 0.001; SA: 51%, n = 24, all
P < 0.001).
To determine whether the observed increase in sphingolipids
following transient coronary occlusion was related to myocar-
dial necrosis or cardiac ischaemia per se, serum troponin levels
were measured. Elevated 12 h troponin T levels were detectable in
only 10 of 31 study subjects (32.3%), following PCI (Figure 3A),
whereas S1P concentrations were elevated in all subjects stud-
ied. Figure 3B shows 12 h troponin T levels plotted against peak
S1P level in the study participants. For those individuals in
whom troponin T was detectable at 12 h, a strong correlation
was found between peak serum SIP levels and 12 h troponin
T level (R2 = 0.818; P < 0.0001). Furthermore no significant
changes occurred in hsTnT levels in either the coronary sinus
(n = 6) or peripheral blood (n = 12) at 1 and 5min time points
after transient coronary occlusion as shown in Figures 3C,D,
respectively.
Oxidized LDL (OxLDL) was measured as a biomarker of
oxidative stress in the serum samples obtained. OxLDL levels
in coronary sinus and peripheral blood at different time points
are shown in Figures 4A,B, respectively. At 1min following bal-
loon inflation, in coronary sinus, levels of OxLDL increased by
16%, compared with baseline levels (n = 7, P = 0.29), whereas in
www.frontiersin.org June 2013 | Volume 4 | Article 130 | 3
Egom et al. Sphingolipids in myocardial ischaemia
Table 2 | Plasma levels of sphingolipids in coronary sinus and peripheral blood in patients who underwent PCI.
Time Coronary sinus (µmol per liter) n = 7 Peripheral (µmol per liter) n = 24
S1P SPH SA S1P SPH SA
Baseline 123.34 ± 7 27.19 ± 9 0.44 ± 0.28 1.23 ± 0.27† 0.31 ± 0.004† 0.0009 ± 0.0002†
1min 509.13 ± 86* 58.45 ± 5* 3.14 ± 0.35* 2.31 ± 0.06*† 0.52 ± 0.002*† 0.0032 ± 0.001*†
5min 1008.8 ± 152* 59 ± 1.08* 1.85 ± 0.14* 11.48 ± 2.70*† 0.45 ± 0.005*† 0.0013 ± 0.0001*†
12 h N/A N/A N/A 2.42 ± 0.20* 0.21 ± 0.001 0.0004 ± 0.00004
Concentrations are shown for baseline (pre-balloon inflation) and at 1 and 5min post-inflation both for coronary sinus and peripheral and also 12h post-PCI for
peripheral samples. Values are expressed as mean ± sem. N/A denotes not available.
∗P < 0.001 for the comparison between the baseline vs. 1 and 5min post-balloon inflation.
†P < 0.001 for comparison between coronary sinus and peripheral levels.
FIGURE 1 | Distribution of sphingolipids in coronary sinus blood
(A; n = 7) and in peripheral blood (B; n = 24) in patients who
underwent PCI. Also shown are comparative distributions of
sphingolipids in peripheral blood at baseline (before balloon inflation in a
patient) and in a blood sample from a healthy control (C; n = 11).
Representative examples of relative plasma levels of sphingolipids as
detected by HPLC at baseline and at different time points: 1, 5min, and
12h post-PCI are shown.
peripheral blood, levels increased by 29% compared with baseline
(n = 24, all P < 0.001). Peripheral OxLDL levels were consis-
tently lower than coronary sinus levels. At 5min after balloon
inflation, in coronary sinus blood, levels of OxLDL increased
by 42% compared with baseline (n = 7, all P < 0.001), while in
peripheral blood, levels of OxLDL increased by 60% compared
with baseline (n = 24, all P < 0.001). At 12 h following the PCI
procedure, levels of OxLDL increased by 82% compared with
baseline (n = 7, all P < 0.001 95% CI).
hsCRP levels were measured as a general marker of inflamma-
tion. No significant changes occurred in hsCRP levels in coronary
sinus and peripheral blood at different time points as shown in
Figures 5A,B, respectively.
DISCUSSION
This study demonstrated for the first time plasma sphingolipid
behavior following transient cardiac ischaemia in humans, with
dramatic increases in S1P, SPH, and SA. Levels were markedly
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FIGURE 2 | Changes in sphingolipid concentrations in coronary sinus blood: S1P (A); SPH (B); and SA (C) and comparative concentrations in
peripheral blood for S1P (D); SPH (E); and SA (F), at different time course points following balloon inflation.
increased in both the coronary sinus and peripherally within
1min of transient ischaemia mediated by short periods of coro-
nary vessel occlusion. To date, no biomarker used in clinical
practice has the ability to detect such transient episodes of cardiac
ischaemia as we observed with sphingolipids.
Cardiac biomarkers, such as cardiac troponins, have become
the standard test in combination with clinical and electrocar-
diographic findings to diagnose and risk stratify patients with
ACS. Recently two studies reported the early diagnosis of MI with
high sensitive troponin assays, demonstrating this to be more
accurate in diagnosing MI, compared to the conventional tro-
ponin test and other markers (Keller et al., 2009). These high
sensitivity tropnin assays have high diagnostic specificity and sen-
sitivity for the diagnosis of ACSs after only 2 or 3 h following the
onset of chest pain (Keller et al., 2009; Bonaca et al., 2010). The
enhancements in troponin assays have enabled resolution of the
99th percentile reference limit at progressively lower concentra-
tions. However, the clinical significance of low-level increases with
sensitive assays is still debated (Bonaca et al., 2010).
Plasma S1P, SPH, and SA levels are more sensitive mark-
ers of transient cardiac ischaemia in the subjects studied in this
report compared to either hsTnT or regular TnT since we did
not observe a significant elevation of hsTnT in coronary samples
of the subjects at 1 and 5mins following PCI despite marked
changes in sphingolipid levels. Indeed, previous studies have
shown that the greatest diagnostic utility of hsTnT is between 2
and 6 h following ischemic insult (Keller et al., 2009; Bonaca et al.,
2010) which is several orders of magnitude longer than we have
observed with our sphingolipid markers. Furthermore, elevated
troponin T level was detectable at 12 h following PCI in 10 of 31
study subjects (32.3%).
Significant changes observed in oxidized LDL, a biomarker
of oxidative stress, over the same time-course as the changes in
sphingolipids may suggest a role for oxidative stress in the regu-
lation of sphingolipid metabolism as described in animal studies
(Maceyka et al., 2007). The peripheral baseline ox-LDL levels in
our study are similar to those reported by Holvoet et al. (1998)
in their comparison of ox-LDL levels between healthy controls
and CAD patients. Tsimikas and co-workers found, in patients
presenting at the Emergency Room with chest pain, that circu-
lating ox-LDL specific markers strongly reflect the presence of
ACS (Holvoet et al., 2006). Ehara et al. showed that plasma ox-
LDL levels were significantly higher in AMI patients than in stable
angina patients (Ehara et al., 2008) Interestingly, themagnitude of
increase of ox-LDL observed in our study was much greater than
those observed in AMI patients in Ehara et al.’s study suggesting
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FIGURE 3 | Relationship between troponin T levels at 12h (A)
and peak S1P levels (B) in the study participants. In those
cases where troponin T was detectable there was close correlation
between troponin T and S1P levels (R2 = 0.818; P < 0.0001). (C,D)
Changes in hsTnT concentration in coronary sinus blood and
peripheral blood.
that such an increase would be unlikely due to a rupture of
unstable plaques. Buffon et al. (2000) have similarly observed
transient (<15min’ duration) elevation of free lipid peroxides in
the coronary sinus during balloon occlusion of the left anterior
descending coronary artery. It is possible that ROS generated sec-
ondary to such ischemic insults may oxidize phospholipids in the
vessel wall or even in plasma, which would then be subsequently
detected as OxLDL in plasma. It is well-known that during the
onset of hypoxia, ROS activates neutral sphingomyelinase, gen-
erating ceramide. Furthermore, ROS also leads to activation of
Sphingosine Kinase 1 in a PKC-dependent manner (Jin et al.,
2002), hence some of this ceramide may be metabolized to S1P
thereby increasing S1P levels, in line with our observations.
Indeed, the differences in sphingolipid response observed dur-
ing cardiac ischaemia between our study and that of Knapp et al.
(2009) in which they observed a decrease in S1P levels following
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FIGURE 4 | Changes in Ox-LDL concentrations in coronary sinus (A) and peripheral (B) blood at different time course points following balloon
inflation.
FIGURE 5 | Changes in CPR concentrations in Coronary sinus (A) and peripheral (B) blood at different time course points following balloon inflation.
MI may be due to the more prolonged ischaemia during MI
resulting in degradation of sphingosine kinase 1 (Maceyka et al.,
2007) and an inhibition of its activity mediated by ROS leading to
decreased levels of S1P and its metabolites (Knapp et al., 2009).
Distinct changes in levels of S1P, SPH, and SA over the 12 h
time course of sampling reflect the complex dynamic metabolism
or inter-conversion of these three sphingolipids in the coronary
and peripheral circulation. Yatomi et al. (1995) showed that about
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50% of SPH was converted to S1P within 5min in intact platelets
and plasma. These results may explain why our SPH plasma
levels tend to decrease and S1P increases after 5min. S1P has
been found to be metabolically stable for at least 2 h (Yatomi
et al., 1995) so once released from cardiac myocytes is likely to
circulate in the body, which could account for the 11% of the
5min S1P peripheral blood levels that was still detectable at 12 h.
Consistently, Sattler et al showed that S1P levels in plasma rise
during the first 12 h of MI and decline thereafter. The authors
demonstrated that in this setting plasma high density lipoprotein-
C (HDL-C), but not other carriers, is the acceptor of S1P as
mirrored by the increase in their S1P content to concentrations
exceeding even those of healthy HDL (Sattler et al., 2010). The
decrease in levels of SA may also be attributed to its very fast
turnover (Yatomi et al., 1997).
Our study also indicates a potential role of sphingolipids
in pathophysiological processes that occur during early cardiac
ischaemia. Vessey and colleagues have demonstrated that sph-
ingolipids are important endogenous cardioprotectants released
by ischemic pre- and post-conditioning in experimental animal
models (Vessey et al., 2009) and pre-treatment with exogenous
S1P provides protection against cardiac I/R injury (Karliner,
2009). Kelly et al. have shown that ethanolamine, a metabolite
of S1P protects the murine heart against I/R injury via activa-
tion of STAT-3 (Kelly et al., 2010). In addition, Theilmeier et al.
have shown that the HDL and its constituent, S1P, acutely pro-
tect the heart against ischaemia/reperfusion injury in vivo via an
S1P3-mediated and nitric oxide-dependent pathway, suggesting
that a rapid therapeutic elevation of S1P-containing HDL plasma
levels may be beneficial in patients at high risk of acute myocar-
dial ischaemia (Theilmeier et al., 2006). Interestingly, Sattler
et al. have recently shown that the amount of plasma S1P not
bound to HDL and the ratio of non-HDL-bound and HDL-
bound S1P in plasma are increased in patients with stable CAD
and MI compared to healthy individuals and are correlated to
the clinical severity of CAD symptoms (Sattler et al., 2010). In
addition the authors also found that the amount of plasma S1P
not bound to HDL is inversely associated with the S1P content
of isolated HDL only in healthy individuals but not in patients
with CAD, implying a functional alteration in the S1P exchange
between HDL-bound and non-HDL-bound S1P plasma pools in
CAD. We recently found that the S1P receptor agonist, FTY720,
a new generation of S1P receptor modulator in phase III clin-
ical trials as an immuno-suppressant agent for the treatment
of auto-immune diseases and in organ transplantation (Budde
et al., 2006), can prevent ischaemia-reperfusion damage in iso-
lated heart and sino-atrial (SA) nodes in the rat (Egom et al.,
2010a). We also showed that FTY720 reduces ischaemia-induced
ventricular arrhythmias and SA nodal dysfunction via activa-
tion of p21-activated kinase (Pak1), a Ser/Thr kinase downstream
of small G-proteins, and Akt (Egom et al., 2010a,b). FTY720
may also inhibit atherosclerosis by suppressing the machinery
involved in monocyte/macrophage emigration to atherosclerotic
lesions (Keul et al., 2007). In contrast to S1P receptors on lym-
phocytes, the authors also demonstrated that FTY720 did not
desensitize vascular S1P receptors suggesting that S1P agonists
that selectively target the vasculature and not the immune system
may be promising new drugs against atherosclerosis (Keul et al.,
2007). In addition, S1P3 receptor may mediate the chemotac-
tic effect of S1P in macrophages in vitro and in vivo and may
play a causal role in atherosclerosis by promoting inflammatory
monocyte/macrophage recruitment and altering smooth muscle
cell behavior (Keul et al., 2011).
Recently, several novel biomarkers including hFABP (Colli
et al., 2007) and cMyBP-C (Govindan et al., 2012) have been
proposed. hFABP is a small soluble cytosolic protein involved
in the transportation of long-chain fatty acids into the car-
diomyocyte is released rapidly into the circulation in response to
cardiomyocyte injury. Due to its solubility, hFABP can be released
more rapidly than structurally bound molecules like cardiac tro-
ponins. Furthermore, it may enter the vascular system directly via
endothelium because of its small size (15 kDA). Thus, hFABP is
regarded as an early sensitive marker of AMI (Colli et al., 2007).
Cardiac myosin binding protein-C (cMyBP-C) is a thick filament
assembly protein that stabilizes sarcomeric structure and regulates
cardiac function; however, the profile of cMyBP-C degradation
after MI is unknown (Govindan et al., 2012).
Are sphingolipids mechanistically relevant to ischaemia-
related arrhythmias? We have recently demonstrated that the
S1P agonist FTY720 may reduce ischaemia-induced ventricular
arrhythmias and SA nodal dysfunction via activation of Pak1, a
Ser/Thr kinase downstream of small G-proteins, and Akt (Egom
et al., 2010a). The detailed mechanisms underlying this protective
effect is likely to be complex, and may involve primary effects on
ion channels/transporters and secondary effect to protect cardiac
myocytes from hypoxia-or ischemia-induced stress and cell death.
Both S1P and FTY720 may have functional effect through IK,ACh
as suggested by previous studies (Guo et al., 1999; Koyrakh et al.,
2005).
The current study has number of limitations. Firstly, the study
was conducted in a limited number of patients hence larger stud-
ies are needed to validate the value of serum sphingolipids level
in the early detection of cardiac ischaemia. Secondly, transient
balloon dilatation is a very different process from plaque rupture
and thrombus/emboli occlusion in clinical situation. Therefore,
the clinical implication of the findings in this study need to be
further studied in larger number of cases of ACSs. Thirdly, since
this was a prospective, observational study, we cannot quantify
the clinical effect associated with the increase in early diagnostic
accuracy. Fourthly, the specificity of serum sphingolipids in the
early detection of cardiac ischaemia is uncertain, since it is possi-
ble that sphingolipidsmay also be elevated in other cardiovascular
diseases as well as in situations such as sepsis and a variety of
other inflammatory processes that evoke the release of inflam-
matory cytokines and involve the TNF pathway. However, hsTnT
have also been shown to be elevated in aortic dissection, valvu-
lar heart disease and acute decompensated heart failure (Keller
et al., 2009). Finally, it is still to be decided whether the eleva-
tion in Sphingolipids from these patients is derived from vascular
trauma due to PCI or frommyocardial ischaemia and/or necrosis,
although the strong correlation with 12 h troponin levels would
suggest that they are less likely to be derived from vascular trauma
alone. In addition, there is no significant correlation between
ECG changes (ischaemia phenotype) and plasma levels of S1P,
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SPH, and SA, This may be due to a limited number of patients
involved in this cohort. However, even in those patients who did
not have ECG changes, ischemic symptoms were experienced.
In conclusion, we demonstrate the behavior of plasma sphin-
golipids level in transient cardiac ischaemia in humans produced
by transient coronary vessel occlusion observed during PCI. The
results show a dramatic increase in plasma S1P, SPH, and SA
levels at very early stages of ischaemia, correlating strongly with
Troponin levels 12 h post-PCI. These molecules therefore may
become novel potentially robust early predictors of acute myocar-
dial ischaemia presenting with ACS therefore provide a crucial
timing window for treating this condition for preventing the
occurrence of fatal ventricular arrhythmias. This study also raises
the question of whether modulating the sphingolipid pathway
may lead to potential therapeutic benefit both before and during
an ischemic coronary event.
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